{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":2,"sponsored":0,"items":[{"id":"n_czvdx2brpgp766zfqvqq","seq":661191,"kind":"article","title":"BeyondSpring Gets FDA Fast Track For Plinabulin In Lung Cancer","url":"https://www.finanzen.ch/nachrichten/aktien/beyondspring-gets-fda-fast-track-for-plinabulin-in-lung-cancer-1036581094","published":"2026-09-29T11:56:25Z","seen":"2026-09-29T11:56:25Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","business"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q15269699","name":"plinabulin","type":"other"},{"id":"Q47912","name":"lung cancer","type":"other"}],"story":"st_czvdx2brpgp766zfqvqq","category":"health","category_p":0.42,"sentiment":"positive","tone":0.11,"political":0.07},{"id":"n_mee6zfe2qytmjgagc7ta","seq":647786,"kind":"press_release","title":"BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis","url":"https://www.globenewswire.com/news-release/2026/09/29/3370683/0/en/beyondspring-announces-fda-fast-track-designation-for-plinabulin-in-post-ici-non-squamous-nsclc-and-strategic-transaction-to-advance-global-phase-3-dublin-4-trial-toward-planned-in.html","summary":"FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment of cancer and other diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) without…","published":"2026-09-29T11:01:00Z","seen":"2026-09-29T11:07:24Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:bysi","kyg108301006"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q15269699","name":"plinabulin","type":"other"},{"id":"Q899151","name":"Imperial Chemical Industries","type":"other"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"mentions":2,"story":"st_mee6zfe2qytmjgagc7ta","category":"health","category_p":0.33,"category2":"science-technology","sentiment":"neutral","tone":0.19,"political":0.06}]}